Library Subscription: Guest
Begell Digital Portal Begell Digital Library eBooks Journals References & Proceedings Research Collections
Critical Reviews™ in Oncogenesis
SJR: 0.631 SNIP: 0.503 CiteScore™: 2

ISSN Print: 0893-9675
ISSN Online: 2162-6448

Critical Reviews™ in Oncogenesis

DOI: 10.1615/CritRevOncog.v13.i4.10
pages 265-282

Methylation-Based Biomarkers for Early Detection of Urological Cancer

Rui Manuel Ferreira Henrique
Department of Pathology, Portuguese Oncology Institute—Porto; and Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Sa-lazar (ICBAS), University of Porto, Portugal
Vera L. Costa
Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Sa-lazar (ICBAS), University of Porto, Portugal
Carmen Jeronimo
Cancer Biology & Epigenetics Group, Research Center, Portuguese Oncology Institute-Porto (Cl-IPO-Porto), Rua Dr. Antonio Bernardino Almeida, 4200-072, Porto, Portugal; Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences

ABSTRACT

Genitourinary (prostate, bladder, and kidney) cancers together comprise the most common type of human neoplasms. As a common feature to these types of malignancy, the disease is frequently asymptomatic at its earlier stages, when curative treatment is most likely to be successful. Moreover, available tests for genitourinary cancer screening (mostly directed to prostate cancer) are characterized by variable (usually low) sensitivity and specificity, preventing a consensual support for their routine use by the medical community. Thus, the timely and accurate detection of GU cancer remains a significant clinical challenge. Over the last decade, a new generation of cancer biomarkers, based on the characterization of the methylome, has emerged and has showed promise in the detection of several common malignant tumors. The investigation of novel genitourinary cancer methylation-based markers constitutes an attractive and fast-growing research field, and several studies reported on the feasibility of examining these markers in body fluids (urine and blood) for early, noninvasive cancer detection. Importantly, the use of quantitative, high-throughput techniques enables relatively easy and reproducible detection of hypermethylation at multiple gene loci in a single test, thus facilitating its translation to the clinics. Although available data is still insufficient to support the clinical implementation of these markers at the present time, further developments in methylation analysis are likely to provide valuable tests for genitourinary cancer screening and management.


Articles with similar content:

Liquid Biopsies in the Management of Bladder Cancer: Next-Generation Biomarkers for Diagnosis, Surveillance, and Treatment-Response Prediction
Critical Reviews™ in Oncogenesis, Vol.22, 2017, issue 5-6
Monica Cheng, Hristos Z. Kaimakliotis, Shaobo Zhang, Catherine R. Miller, Antonio Lopez-Beltran, Michael O. Koch, Yu Yang, Rodolfo Montironi, Liang Cheng
Liquid Biopsies for Assessing Metastatic Melanoma Progression
Critical Reviews™ in Oncogenesis, Vol.21, 2016, issue 1-2
Dave S.B. Hoon, Kelly Huynh
Theranostic Nanostructures for Ovarian Cancer
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.36, 2019, issue 4
Bankuru Navyatha, Seema Nara
An Experimental Platform for Characterizing Cancer Biomarkers with Capabilities in Noninvasive and Continuous Screening
Critical Reviews™ in Biomedical Engineering, Vol.47, 2019, issue 3
Mackenzie M. Honikel, Jeffrey T. La Belle
Tissue Cross-Talk and Exosomal-MicroRNAs
Forum on Immunopathological Diseases and Therapeutics, Vol.6, 2015, issue 3-4
Micol Marchetti